Alembic, Natco, 3 more firms to make anti-black fungus drug: Centre

Companies have also placed orders for importing 600,000 vials of Amphotericin-B, says Union minister Mansukh Mandaviya

Black fungus
Doctors perform a Diagnostic Nasal Endoscopy (DNE) on a patient to detect Black Fungus at NSCB medical college and hospital in Jabalpur (Photo: PTI)
Press Trust of India New Delhi
2 min read Last Updated : May 20 2021 | 9:08 PM IST

The shortage of Amphotericin-B, a drug used for treating mucormycosis, will be resolved soon as various new drug firms have got approvals to manufacture the drug, Union minister Mansukh Mandaviya said on Thursday.

Mucormycosis, also known as Black Fungus, damages the nose, eyes, sinuses, and sometimes even the brain.

"Black Fungus (Mucormycosis) curing drug #AmphotericinB's shortage will be resolved soon! Within three days, 5 more Pharma companies have got New Drug Approval for producing it in India, in addition to the existing 6 pharma companies," Mandaviya said in a tweet.

Mandaviya, who is the Minister of State for Chemicals and Fertilizers, also said that existing pharma companies have already started ramping up the production of the drug.

"Indian Companies have also placed orders for importing 6 lakh vials of #AmphotericinB. We are leaving no stone unturned to smoothen the situation," he noted.

Further, he said that Emcure Pharmaceuticals, Natco Pharma, Gufic Biosciences, Alembic Pharmaceuticals and Lyca Pharmaceuticals have received approval for production of Amphotericin-B in recent days.

Companies like Mylan, BDR Pharma, Sun Pharma and Cipla are already into the manufacturing of the drug, he added.

Mucormycosis is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables. It affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immuno-compromised individuals such as cancer patients or people with HIV/AIDS.

The doctors in India are documenting an alarming number of cases of mucormycosis among patients with COVID-19 and those who have recently recovered. They believe that mucormycosis may be triggered by the use of steroids, a life-saving treatment for severe and critically ill COVID-19 patients.

Rajasthan government has declared Black Fungus as an epidemic while other states like Telangana and Tamil Nadu have marked it as a notifiable disease.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: May 20 2021 | 9:06 PM IST

Next Story